Summary
Twenty-three patients with advanced refractory multiple myeloma were treated with a combination chemotherapeutic regimen consisting of four-day continuous infusion of vincristine and doxorubicin plus intermittent high-dose dexamethasone (VAD). All patients included in the study were heavily pretreated with cytostatics and radiotherapeutic measures, and generally presented in poor general condition. In 3 of the 16 evaluable patients (18%) a response, and in 7 patients (44%) an improvement as defined by a reduction in tumor mass by more than 50% was achieved. Six patients had progressive disease. Evaluation of survival for responders (15 mos) versus non-responders (2 mos) by the landmark method seems to confirm the relative therapeutic efficacy of the VAD protocol in refractory multiple myeloma. The somewhat inferior response rate as well as the occurrence of considerable toxicity in several cases (when compared to the recent M. D. Anderson trial) may be related to differences in clinical features and pretreatment status of the two studies' population.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alexanian R, Bonnet J, Gehan E, Haut A, Hewlett J, Lane M, Monto R, Wilson H (1972) Combination chemotherapy for multiple myeloma. Cancer 30: 382–389
Alexanian R, Salmon SE, Bonnet J, Gehan E, Haut A, Weick J (1977) Combination therapy for multiple myeloma. Cancer 40: 2756–2771
Alexanian R, Yap BS, Bodey GP (1983) Prednisone pulse therapy for refractory myeloma. Blood 62: 572–577
Barlogie B, Smith L, Alexanian R (1984) Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310: 1353–1356
Bonnet J, Alexanian R, Salmon SE, Bottomley R, Amare M, Haut A, Dixon D (1982) Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a South West Oncology Group study. Cancer Treat Rep 66: 1267–1271
Bonnet J, Alexanian R, Salmon SE, Haut A, Dixon DO (1984) Addition of cisplatin and bleomycin to vincristine-carmustine-prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a South West Oncology Groups study. Cancer Treat Rep 68: 481–485
Durie BGM, Salmon SE (1975) A clinical staging system for multiple myeloma. Cancer 36: 842–854
Kaplan E, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481
Kyle RA, Pajac TF, Henderson ES, Havabi IV, Brunner K, Henry PH, McIntre OR, Holland JF (1982) Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone. Cancer Treat Rep 66: 451–456
Scheithauer W, Ludwig H, Maida E (1985) Acute encephalopathy associated with continuous vincristine sulfate combination therapy: case report. Invest New Drugs 3: 315–318
Alexanian R, Barlogie B, Dixon D (1986) High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 105: 8–11
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Scheithauer, W., Cortelezzi, A., Kutzmits, R. et al. VAD protocol for treatment of advanced refractory multiple myeloma. Blut 55, 145–152 (1987). https://doi.org/10.1007/BF00320568
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00320568